ルート検索

住所を入力して検索ボタンをクリックすると、ルートが表示されます。

メールアドレス :   

登録内容

  • [登録者] : Centers for Medicare & Medicaid Services (CMS)
  • [言語]日本語
  • [エリア]Baltimore, MD
  • 登録日 : 2024/08/16
  • 掲載日 : 2024/08/16
  • 変更日 :2024/08/16
  • 総閲覧数 : 39 人
お知らせ

Status Update - MolDX: Molecular Testing for Solid Organ Allograft Rejection Proposed LCD

Centers for Medicare & Medicaid Services

The Medicare Administrative Contractors (MACs) have carefully considered all the feedback received from interested parties regarding the MolDx: Molecular Testing for Solid Organ Allograft Rejection proposed local coverage determination (LCD).  In response to public comments and upon further review of the evidence, the MACs are not finalizing the proposed LCD issued on August 10, 2023. Due to the importance of identifying solid organ allograft rejection early and to ensure the public has additional opportunities to comment on the policy, the MACs intend to issue a new LCD in the coming months. When posted, the new proposed LCD will be available for review in the Medicare Coverage Database (MCD) at https://www.cms.gov/medicare-coverage-database/search.aspx 

At this time, neither CMS nor the MACs have changed coverage for these blood tests that monitor for organ transplantation rejection when ordered by their physicians in medically appropriate circumstances. Patients with transplanted hearts, lungs, or kidneys who meet Medicare’s existing local coverage criteria [ https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38629&ver=3&keyword=allograft&keywordType=starts&areaId=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1 ]can continue to access these blood tests, including under the following circumstances:


* When there are signs or symptoms of rejection;
* After a physician-assessed pretest, including for surveillance testing;
* After an indeterminate biopsy;
* As a replacement for a biopsy when deemed clinically appropriate by the patient’s qualified physician; and
* For evaluation of the adequacy of immunosuppression. 

The Medicare coverage database will be fully updated to reflect this decision next week.

 

________________________________________________________________________

If you have any questions about this update, please email caginquiries@cms.hhs.gov.

You're getting this message because you subscribed to get email updates from the Centers for Medicare & Medicaid Services (CMS) [ http://www.cms.gov/ ].

Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page [ https://public.govdelivery.com/accounts/USCMS/subscriber/edit?preferences=true#tab1 ]. You will need to use your email address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com [ https://subscriberhelp.govdelivery.com/ ].

This service is provided to you at no charge by Centers for Medicare & Medicaid Services (CMS) [ http://www.cms.gov ].


________________________________________________________________________

This email was sent to mshinji3056@gmail.com using GovDelivery Communications Cloud 7500 Security Boulevard · Baltimore MD 21244


body .abe-column-block { min-height: 5px; } table.gd_combo_table img {margin-left:10px; margin-right:10px;} table.gd_combo_table div.govd_image_display img, table.gd_combo_table td.gd_combo_image_cell img {margin-left:0px; margin-right:0px;} table.govd_hr {min-width: 100%;}

びびなび - 自治体からのお知らせ

印刷された情報をサイトで見るには、上記URLまたはQRコードからアクセスできます。